A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).
- EligibilityCriteria: Inclusion Criteria:  Subject has a confirmed diagnosis of Notalgia Paresthetica. Subject has a history of chronic pruritus (itch) due to Notalgia Paresthetica. Subject has moderate to severe pruritus. Subject is able and competent to read and sign the informed consent form (ICF).  Exclusion Criteria:  Subject has chronic pruritus that is related to a condition other than Notalgia Paresthetica. Subject with known or suspected history of a clinically significant systemic disease, unstable medical disorders, life-threatening disease, including physical/laboratory/ECG/vital signs abnormality that would put the subject at undue risk or interfere with interpretation of study results Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult